HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report) gapped up before the market opened on Thursday . The stock had previously closed at $17.15, but opened at $17.59. HUTCHMED shares last traded at $17.53, with a volume of 25,921 shares traded.
Analyst Upgrades and Downgrades
Several brokerages have recently weighed in on HCM. Wall Street Zen lowered HUTCHMED from a "strong-buy" rating to a "buy" rating in a research report on Saturday. HSBC lowered HUTCHMED from a "buy" rating to a "hold" rating in a research report on Tuesday, May 13th.
View Our Latest Research Report on HCM
HUTCHMED Trading Down 4.6%
The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.68 and a current ratio of 2.81. The firm has a 50-day moving average price of $14.35 and a two-hundred day moving average price of $14.73.
Institutional Investors Weigh In On HUTCHMED
Several hedge funds and other institutional investors have recently made changes to their positions in HCM. ABC Arbitrage SA purchased a new position in HUTCHMED during the 4th quarter worth approximately $500,000. OLD Mission Capital LLC purchased a new position in HUTCHMED during the 4th quarter worth approximately $230,000. Renaissance Technologies LLC grew its stake in HUTCHMED by 18.4% during the 4th quarter. Renaissance Technologies LLC now owns 188,539 shares of the company's stock worth $2,717,000 after buying an additional 29,239 shares during the last quarter. Barclays PLC grew its stake in HUTCHMED by 1,483.6% during the 4th quarter. Barclays PLC now owns 2,407 shares of the company's stock worth $35,000 after buying an additional 2,255 shares during the last quarter. Finally, Marshall Wace LLP purchased a new position in HUTCHMED during the 4th quarter worth approximately $261,000. Institutional investors and hedge funds own 8.82% of the company's stock.
About HUTCHMED
(
Get Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Further Reading
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
